Structural changes in the retina and serum HMGB1 levels are associated with decreased cognitive function in patients with Parkinson's disease
Background: Cognitive impairment is a serious nonmotor symptom in patients with Parkinson's disease (PD). Currently, there are few studies investigating the relationship of serum markers and retinal structural changes with cognitive function in PD. Objective: To investigate the relationship bet...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Neurobiology of Disease |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996123003959 |
| _version_ | 1797364240357523456 |
|---|---|
| author | Keke Liang Xiaohuan Li Qingge Guo Jianjun Ma Hongqi Yang Yongyan Fan Dawei Yang Xiaoxue Shi Zonghan She Xuelin Qi Qi Gu Siyuan Chen Jinhua Zheng Dongsheng Li |
| author_facet | Keke Liang Xiaohuan Li Qingge Guo Jianjun Ma Hongqi Yang Yongyan Fan Dawei Yang Xiaoxue Shi Zonghan She Xuelin Qi Qi Gu Siyuan Chen Jinhua Zheng Dongsheng Li |
| author_sort | Keke Liang |
| collection | DOAJ |
| description | Background: Cognitive impairment is a serious nonmotor symptom in patients with Parkinson's disease (PD). Currently, there are few studies investigating the relationship of serum markers and retinal structural changes with cognitive function in PD. Objective: To investigate the relationship between retinal structural changes, serum high mobility group box-1 (HMGB1) levels and cognitive function and motor symptoms in PD patients. Methods: Eighty-nine participants, including 47 PD patients and 42 healthy subjects, were enrolled. PD patients were divided into Parkinson's disease with normal cognitive (PD-NC), Parkinson's disease with mild cognitive impairment (PD-MCI), and Parkinson's disease with dementia (PDD) groups. The motor and nonmotor symptoms of PD patients were evaluated with clinical scale. Serum HMGB1 levels were detected by enzyme-linked immunosorbent assay (ELISA), and ganglion cell-inner plexiform layer complex (GCIPL) thickness changes in the macula were quantitatively analyzed by swept source optical coherence tomography (SS-OCT) in all patients. Results: Compared with the control group, the macular GCIPL (t = −2.308, P = 0.023) was thinner and serum HMGB1 (z = −2.285, P = 0.022) was increased in PD patients. Macular GCIPL thickness in patients with PD-MCI and PDD were significantly lower than that in PD-NC patients, but there were no significant difference between the PD-MCI and PDD groups. Serum HMGB1 levels in patients with PD-MCI and PDD were significantly higher than those in PD-NC patients, and serum HMGB1 levels in PDD patients were higher than those in PD-MCI patients. Correlation analysis showed that serum HMGB1 levels in PD patients were positively correlated with disease duration, HY stage, UPDRS-I score, UPDRS-III score, and UPDRS total score and negatively correlated with MOCA score. Macular GCIPL thickness was negatively correlated with HY stage and positively correlated with MOCA score, and macular GCIPL thickness was negatively correlated with serum HMGB1 level. Logistic regression analysis showed that elevated serum HMGB1 level, thinner macular GCIPL thickness, and higher HY stage were independent risk factors for Parkinson's disease with cognitive impairment (PD-CI). The areas under the receiver operating characteristic curve (AUC) for the serum HMGB1 level and macular GCIPL thickness-based diagnosis of PD-MCI, PDD and PD-CI based on in patients with PD were 0.786 and 0.825, 0.915 and 0.856, 0.852 and 0.841, respectively. The AUC for the diagnosis of PD-MCI, PDD and PD-CI with serum HMGB1 level and GCIPL thickness combined were 0.869, 0.967 and 0.916, respectively. Conclusion: The macular GCIPL thickness and serum HMGB1 level are potential markers of cognitive impairment in PD patients, and their combination can significantly improve the accuracy of the diagnosis of cognitive impairment in PD. |
| first_indexed | 2024-03-08T16:32:27Z |
| format | Article |
| id | doaj.art-94cf5a0051a54cf096b267d9de33d10a |
| institution | Directory Open Access Journal |
| issn | 1095-953X |
| language | English |
| last_indexed | 2024-03-08T16:32:27Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Neurobiology of Disease |
| spelling | doaj.art-94cf5a0051a54cf096b267d9de33d10a2024-01-06T04:38:29ZengElsevierNeurobiology of Disease1095-953X2024-01-01190106379Structural changes in the retina and serum HMGB1 levels are associated with decreased cognitive function in patients with Parkinson's diseaseKeke Liang0Xiaohuan Li1Qingge Guo2Jianjun Ma3Hongqi Yang4Yongyan Fan5Dawei Yang6Xiaoxue Shi7Zonghan She8Xuelin Qi9Qi Gu10Siyuan Chen11Jinhua Zheng12Dongsheng Li13Department of Neurology, Henan University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Henan Eye Institute, Henan Eye Hospital, Henan Provincial People's Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, China; Corresponding authors at: Department of Neurology, Henan Provincial People's Hospital, No. 7, Wei Wu Road, Zhengzhou 450003, China.Department of Neurology, Henan University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, China; Corresponding authors at: Department of Neurology, Henan Provincial People's Hospital, No. 7, Wei Wu Road, Zhengzhou 450003, China.Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, ChinaDepartment of Neurology, Henan University People's Hospital, Zhengzhou, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou, ChinaBackground: Cognitive impairment is a serious nonmotor symptom in patients with Parkinson's disease (PD). Currently, there are few studies investigating the relationship of serum markers and retinal structural changes with cognitive function in PD. Objective: To investigate the relationship between retinal structural changes, serum high mobility group box-1 (HMGB1) levels and cognitive function and motor symptoms in PD patients. Methods: Eighty-nine participants, including 47 PD patients and 42 healthy subjects, were enrolled. PD patients were divided into Parkinson's disease with normal cognitive (PD-NC), Parkinson's disease with mild cognitive impairment (PD-MCI), and Parkinson's disease with dementia (PDD) groups. The motor and nonmotor symptoms of PD patients were evaluated with clinical scale. Serum HMGB1 levels were detected by enzyme-linked immunosorbent assay (ELISA), and ganglion cell-inner plexiform layer complex (GCIPL) thickness changes in the macula were quantitatively analyzed by swept source optical coherence tomography (SS-OCT) in all patients. Results: Compared with the control group, the macular GCIPL (t = −2.308, P = 0.023) was thinner and serum HMGB1 (z = −2.285, P = 0.022) was increased in PD patients. Macular GCIPL thickness in patients with PD-MCI and PDD were significantly lower than that in PD-NC patients, but there were no significant difference between the PD-MCI and PDD groups. Serum HMGB1 levels in patients with PD-MCI and PDD were significantly higher than those in PD-NC patients, and serum HMGB1 levels in PDD patients were higher than those in PD-MCI patients. Correlation analysis showed that serum HMGB1 levels in PD patients were positively correlated with disease duration, HY stage, UPDRS-I score, UPDRS-III score, and UPDRS total score and negatively correlated with MOCA score. Macular GCIPL thickness was negatively correlated with HY stage and positively correlated with MOCA score, and macular GCIPL thickness was negatively correlated with serum HMGB1 level. Logistic regression analysis showed that elevated serum HMGB1 level, thinner macular GCIPL thickness, and higher HY stage were independent risk factors for Parkinson's disease with cognitive impairment (PD-CI). The areas under the receiver operating characteristic curve (AUC) for the serum HMGB1 level and macular GCIPL thickness-based diagnosis of PD-MCI, PDD and PD-CI based on in patients with PD were 0.786 and 0.825, 0.915 and 0.856, 0.852 and 0.841, respectively. The AUC for the diagnosis of PD-MCI, PDD and PD-CI with serum HMGB1 level and GCIPL thickness combined were 0.869, 0.967 and 0.916, respectively. Conclusion: The macular GCIPL thickness and serum HMGB1 level are potential markers of cognitive impairment in PD patients, and their combination can significantly improve the accuracy of the diagnosis of cognitive impairment in PD.http://www.sciencedirect.com/science/article/pii/S0969996123003959Parkinson's diseaseCognitive functionHMGB1GCIPLNonmotor symptomsBiomarkers |
| spellingShingle | Keke Liang Xiaohuan Li Qingge Guo Jianjun Ma Hongqi Yang Yongyan Fan Dawei Yang Xiaoxue Shi Zonghan She Xuelin Qi Qi Gu Siyuan Chen Jinhua Zheng Dongsheng Li Structural changes in the retina and serum HMGB1 levels are associated with decreased cognitive function in patients with Parkinson's disease Neurobiology of Disease Parkinson's disease Cognitive function HMGB1 GCIPL Nonmotor symptoms Biomarkers |
| title | Structural changes in the retina and serum HMGB1 levels are associated with decreased cognitive function in patients with Parkinson's disease |
| title_full | Structural changes in the retina and serum HMGB1 levels are associated with decreased cognitive function in patients with Parkinson's disease |
| title_fullStr | Structural changes in the retina and serum HMGB1 levels are associated with decreased cognitive function in patients with Parkinson's disease |
| title_full_unstemmed | Structural changes in the retina and serum HMGB1 levels are associated with decreased cognitive function in patients with Parkinson's disease |
| title_short | Structural changes in the retina and serum HMGB1 levels are associated with decreased cognitive function in patients with Parkinson's disease |
| title_sort | structural changes in the retina and serum hmgb1 levels are associated with decreased cognitive function in patients with parkinson s disease |
| topic | Parkinson's disease Cognitive function HMGB1 GCIPL Nonmotor symptoms Biomarkers |
| url | http://www.sciencedirect.com/science/article/pii/S0969996123003959 |
| work_keys_str_mv | AT kekeliang structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT xiaohuanli structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT qinggeguo structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT jianjunma structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT hongqiyang structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT yongyanfan structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT daweiyang structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT xiaoxueshi structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT zonghanshe structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT xuelinqi structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT qigu structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT siyuanchen structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT jinhuazheng structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease AT dongshengli structuralchangesintheretinaandserumhmgb1levelsareassociatedwithdecreasedcognitivefunctioninpatientswithparkinsonsdisease |